Rivastigmine for delirium in Intensive Care patients, a double-blind, randomised, placebo-controlled, multi-center add-on trial - Rivastigmine for ICU-delirium

• Conditions: Delirium; MedDRA version: 9.1Level: PTClassification code 10012218Term: Delirium; MedDRA version: 9.1Level: LLTClassification code 10012218Term: Delirium; MedDRA version: 9.1Level: LLTClassification code 10012220Term: Delirium due to a general medical condition; MedDRA version: 9.1Level: LLTClassification code 10012226Term: Delirium, cause unknown; MedDRA version: 9.1Level: LLTClassification code 10013758Term: Drug-induced delirium

• Registration Number: EUCTR2007-005300-41-NL
• Lead Sponsor: niversity Medical Center Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02-28
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.18 years or older
2.Admission at an ICU
3. Positive CAM-ICU

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Known allergy to rivastigmine
2. Unable to receive enteric medication
3. Pregnant or lactating
4. Renal replacement therapy
5. Hepatic encephalopathy
6. Second or third degree atrioventricular block
7. Delirium due to benzodiazepine withdrawal.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified